For Health Care Professionals
HALAVEN for another type of cancer

Breast cancer community groups and other support groups

Listed below are some organizations that can give you and your friends and family more information about metastatic breast cancer (mBC) and connect you with other people who have issues like yours.

The American Cancer Society®

www.cancer.org

The American Cancer Society is leading the fight for a world without cancer.

Breastcancer.org

www.breastcancer.org

Discussion Board: http://community.breastcancer.org
Breastcancer.org provides reliable, complete, and up-to-date information on breast cancer and breast health, helping women and their loved ones make the best decisions for their lives.

CancerCare®

www.cancercare.org

Founded in 1944, CancerCare is the leading national organization providing free, professional support services and information to help people manage the emotional, practical and financial challenges of cancer. Their comprehensive services include counseling and support groups over the phone, online and in-person, educational workshops, publications and financial and co-payment assistance. All CancerCare services are provided by oncology social workers and world-leading cancer experts.

Cancer Hope Network

www.cancerhopenetwork.org

Cancer Hope Network provides emotional support to cancer patients, loved ones, and family members by matching them with trained volunteer cancer survivors.

Cancer Support Community

www.cancersupportcommunity.org

As the largest professionally led nonprofit network of cancer support worldwide, the Cancer Support Community delivers $50 million of free services to patients and families each year through 170+ locations, including Gilda’s Club affiliates and hospital partnerships, and a toll-free Helpline and MyLifeLine, a virtual support community for people living with cancer.

Caregiver Action Network

www.helpforcancercaregivers.org

Help for Cancer Caregivers, by the Caregiver Action Network (CAN), is a collaboration of organizations with the goal of improving the health and well-being of the people who care for patients with cancer.

Living Beyond Breast Cancer

www.lbbc.org

Living Beyond Breast Cancer connects people impacted by breast cancer with trusted information and a community of support.

The Metastatic Breast Cancer Alliance

www.mbcalliance.org

The Metastatic Breast Cancer Alliance is dedicated to improving the lives of and outcomes for those living with mBC and their families through increasing awareness and education about the disease and advancing policy and strategic coordination of research funding specifically focused on metastasis that has the potential to extend life, enhance quality of life, and ultimately to cure.

Metastatic Breast Cancer Network

www.mbcn.org

Metastatic Breast Cancer Network (MBCN) is an advocacy group dedicated to patients living with mBC, providing education and information on treatment and on coping with the disease.

METAvivor

www.metavivor.org

METAvivor is passionately committed to women and men living with metastatic breast cancer, raising awareness for the disease and funding research.

MyLifeLine.org

www.mylifeline.org

MyLifeLine.org connects cancer patients and caregivers to their community of family and friends for social and emotional support.

National Coalition for Cancer Survivorship

www.canceradvocacy.org

The National Coalition for Cancer Survivorship (NCCS) is an advocacy organization founded by and for cancer survivors. NCCS promotes policy change to make cancer care better for survivors and their loved ones.

SHARE

www.sharecancersupport.org

SHARE is a national nonprofit that supports, educates, and empowers women affected by breast or ovarian cancer, with a special focus on medically underserved communities. Its peer-model meets women wherever they are with the insight of women who have been there too, creating a nationwide community where no one feels alone. Its free services include support groups, educational tools, expert-led webinars and presentations, a national helpline, online communities, advocacy opportunities, and survivor-patient navigation.

Sharsheret

www.sharsheret.org

Sharsheret is a national nonprofit organization supporting young Jewish women facing breast cancer and their families. Their mission is to offer a community of support to women of all Jewish backgrounds diagnosed with breast cancer or who are at increased genetic risk by fostering culturally-relevant individualized connections with networks of peers, health professionals, and related resources.

Tigerlily Foundation

www.tigerlilyfoundation.org

Tigerlily Foundation is a national breast cancer foundation providing education, awareness, advocacy, and hands-on support to young women ages 15-45—before, during, and after breast cancer.

Young Survival Coalition

www.youngsurvival.org

Young Survival Coalition is dedicated to the critical issues impacting young women diagnosed with breast cancer, offering resources, connections, and outreach.

You are now leaving www.halaven.com

Eisai Inc. does not review the information contained on the following Web site for content, accuracy, or completeness. Use of and access to the information is subject to the terms, limitations, and conditions set by the Web site producer. Eisai Inc. makes no claims about the accuracy or any other aspect of the information contained on this Web site, nor does Eisai Inc. endorse the following Web site.

Please review, then scroll to bottom and tap “Continue” to go to site

Who is HALAVEN® (eribulin mesylate) Injection for?

HALAVEN is a prescription medicine used to treat adults with breast cancer that has spread to other parts of the body, and who have already received other types of anticancer medicines after the cancer has spread.

What safety information do I need to know about HALAVEN?

HALAVEN can cause serious side effects, including

  • Low white blood cell count (neutropenia). This can lead to serious infections that could lead to death. Your health care provider will check your blood cell counts. Call your health care provider right away if you develop fever (temperature above 100.5°F), chills, cough, or burning or pain when you urinate, as any of these can be symptoms of infection

  • Numbness, tingling, or pain in your hands or feet (peripheral neuropathy). Peripheral neuropathy is common with HALAVEN and sometimes can be severe. Tell your health care provider if you have new or worsening symptoms of peripheral neuropathy

  • Your health care provider may delay or decrease your dose or stop treatment with HALAVEN if you have side effects

Before you receive HALAVEN, tell your health care provider about all of your medical conditions, including if you

  • have liver or kidney problems

  • have heart problems, including a problem called congenital long QT syndrome

  • have low potassium or low magnesium in your blood

  • are pregnant or plan to become pregnant. HALAVEN can harm your unborn baby. Tell your health care provider right away if you become pregnant or think you are pregnant during treatment with HALAVEN. Females who are able to become pregnant should use an effective form of birth control during treatment with HALAVEN and for at least 2 weeks after the final dose of HALAVEN and males should use an effective form of birth control when having sex with female partners who are able to become pregnant during treatment with HALAVEN and for 3½ months (14 weeks) after the final dose of HALAVEN

  • are breastfeeding or plan to breastfeed. It is not known if HALAVEN passes into your breast milk. Do not breastfeed during treatment with HALAVEN and for 2 weeks after the final dose of HALAVEN

Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of HALAVEN?

HALAVEN can cause changes in your heartbeat (called QT prolongation). This can cause irregular heartbeats. Your health care provider may do heart monitoring (electrocardiogram or ECG) or blood tests during your treatment with HALAVEN to check for heart problems.

The most common side effects of HALAVEN in adults with breast cancer include low white blood cell count (neutropenia), low red blood cell count (anemia), weakness or tiredness, hair loss (alopecia), nausea, and constipation.

Your health care provider will do blood tests before and during treatment while you are taking HALAVEN.

For more information about HALAVEN, please see full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Who is HALAVEN® (eribulin mesylate) Injection for?

HALAVEN is a prescription medicine used to treat adults with breast cancer that has spread to other parts of the body, and who have already received other types of anticancer medicines after the cancer has spread.

What safety information do I need to know about HALAVEN?

HALAVEN can cause serious side effects, including

  • Low white blood cell count (neutropenia). This can lead to serious infections that could lead to death. Your health care provider will check your blood cell counts. Call your health care provider right away if you develop fever (temperature above 100.5°F), chills, cough, or burning or pain when you urinate, as any of these can be symptoms of infection

  • Numbness, tingling, or pain in your hands or feet (peripheral neuropathy). Peripheral neuropathy is common with HALAVEN and sometimes can be severe. Tell your health care provider if you have new or worsening symptoms of peripheral neuropathy

  • Your health care provider may delay or decrease your dose or stop treatment with HALAVEN if you have side effects

Before you receive HALAVEN, tell your health care provider about all of your medical conditions, including if you

  • have liver or kidney problems

  • have heart problems, including a problem called congenital long QT syndrome

  • have low potassium or low magnesium in your blood

  • are pregnant or plan to become pregnant. HALAVEN can harm your unborn baby. Tell your health care provider right away if you become pregnant or think you are pregnant during treatment with HALAVEN. Females who are able to become pregnant should use an effective form of birth control during treatment with HALAVEN and for at least 2 weeks after the final dose of HALAVEN and males should use an effective form of birth control when having sex with female partners who are able to become pregnant during treatment with HALAVEN and for 3½ months (14 weeks) after the final dose of HALAVEN

  • are breastfeeding or plan to breastfeed. It is not known if HALAVEN passes into your breast milk. Do not breastfeed during treatment with HALAVEN and for 2 weeks after the final dose of HALAVEN

Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of HALAVEN?

HALAVEN can cause changes in your heartbeat (called QT prolongation). This can cause irregular heartbeats. Your health care provider may do heart monitoring (electrocardiogram or ECG) or blood tests during your treatment with HALAVEN to check for heart problems.

The most common side effects of HALAVEN in adults with breast cancer include low white blood cell count (neutropenia), low red blood cell count (anemia), weakness or tiredness, hair loss (alopecia), nausea, and constipation.

Your health care provider will do blood tests before and during treatment while you are taking HALAVEN.

For more information about HALAVEN, please see full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Expand Collapse

Who is HALAVEN® (eribulin mesylate) Injection for?

HALAVEN is a prescription medicine used to treat adults with breast cancer that has spread to other parts of the body, and who have already received other types of anticancer medicines after the cancer has spread.

What safety information do I need to know about HALAVEN?

HALAVEN can cause serious side effects, including

  • Low white blood cell count (neutropenia). This can lead to serious infections that could lead to death. Your health care provider will check your blood cell counts. Call your health care provider right away if you develop fever (temperature above 100.5°F), chills, cough, or burning or pain when you urinate, as any of these can be symptoms of infection

  • Numbness, tingling, or pain in your hands or feet (peripheral neuropathy). Peripheral neuropathy is common with HALAVEN and sometimes can be severe. Tell your health care provider if you have new or worsening symptoms of peripheral neuropathy

  • Your health care provider may delay or decrease your dose or stop treatment with HALAVEN if you have side effects

Before you receive HALAVEN, tell your health care provider about all of your medical conditions, including if you

  • have liver or kidney problems

  • have heart problems, including a problem called congenital long QT syndrome

  • have low potassium or low magnesium in your blood

  • are pregnant or plan to become pregnant. HALAVEN can harm your unborn baby. Tell your health care provider right away if you become pregnant or think you are pregnant during treatment with HALAVEN. Females who are able to become pregnant should use an effective form of birth control during treatment with HALAVEN and for at least 2 weeks after the final dose of HALAVEN and males should use an effective form of birth control when having sex with female partners who are able to become pregnant during treatment with HALAVEN and for 3½ months (14 weeks) after the final dose of HALAVEN

  • are breastfeeding or plan to breastfeed. It is not known if HALAVEN passes into your breast milk. Do not breastfeed during treatment with HALAVEN and for 2 weeks after the final dose of HALAVEN

Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of HALAVEN?

HALAVEN can cause changes in your heartbeat (called QT prolongation). This can cause irregular heartbeats. Your health care provider may do heart monitoring (electrocardiogram or ECG) or blood tests during your treatment with HALAVEN to check for heart problems.

The most common side effects of HALAVEN in adults with breast cancer include low white blood cell count (neutropenia), low red blood cell count (anemia), weakness or tiredness, hair loss (alopecia), nausea, and constipation.

Your health care provider will do blood tests before and during treatment while you are taking HALAVEN.

For more information about HALAVEN, please see full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a health care provider.

All decisions regarding patient care must be made with a health care professional, considering the unique characteristics of the patient.

This site is intended for residents of the United States only. The products discussed herein may have different product labeling in different countries.

To report suspected adverse reactions, contact Eisai Inc. at 1-888-274-2378 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

This Web site contains information relating to various medical conditions and treatment. Such information is provided for educational purposes only and is not meant to be a substitute for the advice of a physician or other health care professionals. You should not use this information for diagnosing a health problem or disease. In order for you to make intelligent health care decisions, you should always consult with a physician or other health care provider for your, or your loved ones', personal medical needs. Individual responses to treatment may vary.

Eisai logo

HALAVEN® is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.

© 2023 Eisai Inc. HALA-US4104 us.eisai.com